ABSTRACT
Introduction
Sepsis is a complex systemic inflammatory syndrome rising in response to severe infection, and is a leading cause of mortality and morbidity worldwide. Eighteen million sepsis cases have been estimated to occur each year, with a mortality rate of nearly 30%. (1) Sepsis is a multifaceted syndrome involving endothelial dysfunction, inflammatory response, immunity, deregulation of intercellular signaling, and cytokine storms. (2, 3) Sepsis is classified as severe when organ dysfunction ensues. Recombinant human activated protein C (drotrecogin alfa-activated) was approved in 2001 by FDA for severe septic patients at high risk of death, with an Acute Physiology and Chronic Health Evaluation (APACHE) II score higher than 25, while the European marketing authorization was guaranteed for patients with severe sepsis and two or more organ failures. Recently, the drug was voluntarily withdrawn from the market by the pharmaceutical company, in response to the findings of a large randomized trial that questioned its risk/benefit ratio in patients with septic shock. (4) Protein C is the plasmatic zymogen, and it is activated in the presence of thrombin -thrombomodulin complex, thus limiting thrombin production (through inactivation of factors Va and VIIIa) while also promoting fibrinolysis. Moreover, it may inhibit cytokine production, neutrophil activation and leukocyte adhesion. (5-8) Protein C shares the same benefits of its activated form (drotrecogin alfa) in septic shock, where it exerts a complex role between immunity, coagulation and inflammation. Protein C seems safer than drotrecogin alfa, with no reported increase in bleeding episodes. However high quality randomized evidence on Protein C is lacking. The finding of a significant positive effect of drotrecogin alfa on patients' mortality could be relevant even if the drug is not commercialized anymore, as a similar but safer and much less studied drug exists: Protein C. We therefore performed a meta-analysis of randomized control trials (RCTs) to assess if drotrecogin alfa-activated can reduce mortality in the more severe septic patients, defined as those with multiple organ failure and a high mortality rate (> 40%).
Materials and methods

Search Strategy
We searched PubMed, Embase, Scopus, BioMedCentral, and the Clinicaltrials.gov database (updated September 1 st 2012) for relevant studies. Search was independently conducted by four trained investigators. The search strategy (9) included any randomized study ever performed on drotrecogin alfaactivated (Xigris ® ; Eli Lilly and Company, Indianapolis, IN, USA) in any clinical setting in humans, and is available in the Appendix. Moreover, pertinent references of retrieved articles and reviews were retrieved to identify more articles. No language restriction was enforced. Study Selection Results from database and literature queries were first independently examined at a title/abstract level by the four investigators, with divergences resolved by consensus. Pertinent articles were retrieved as full text and analyzed adopting the following inclusion criteria: random allocation to treatment and comparison of drotrecogin alfa-activated versus control. There were no restrictions on dose or time of administration. The exclusion criteria were: duplicate data, and non-adult studies. Two investigators independently assessed compliance with selection criteria and selected studies for the final analysis, with divergences finally resolved by consensus. Data Abstraction and Study Characteristics Two authors extracted study end-points and main outcomes, study design, population, clinical setting, and treatment duration. The primary end-point of the present investigation was the mortality rate in high risk patients, identified as having multiple organ dysfunction, and a high mortality rate in controls. A 40% mortality rate was arbitrarily chosen as the cut-off to define high mortality rate. Secondary endpoints were mortality in all patients, mortality in patients with an APACHE 2 score ≥ 25 and in those with an APACHE 2 score ≤25. Internal Validity and Risk of Bias Assessment The internal validity and risk of bias of included trials was appraised by two independent reviewers according to Cochrane Collaboration methods, (10) with divergences resolved by consensus. Publication bias was assessed by visual inspection of funnel plots. Data Analysis and Synthesis Computations were performed with RevMan 5. (11) Statistical heterogeneity and inconsistency were measured using I 2 . Binary outcomes from individual studies were analyzed in order to compute individual and pooled risk ratios (RR) with pertinent 95% confidence intervals (CI, with equivalence set at 1, odds ratio (OR) <1 favoring the first treatment, and OR>1 favoring the second treatment), by means of Mantel-Haenszel method and with random effect model (to better account for clinical and statistical variations). No continuous variables were included in analyses. Statistical significance was set at the two-tailed 0.05 level for hypothesis testing and at 0.10 for heterogeneity testing. Unadjusted P values are reported throughout. This study was performed in compliance with The Cochrane Collaboration and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. (12) Results Database searches and scanning of article bibliographies yielded a total of 214 results. Excluding 188 non-pertinent titles or abstracts, we retrieved in complete form, and assessed according to the selection criteria, 16 studies (figure 1). Six studies were further excluded because they were not randomized. (1,13-17) Two studies were excluded because they involved a pediatric setting. (18, 19) Two were further excluded because they were conducted in other settings, like pancreatitis and pulmonary embolism. (20, 21) One was excluded due to the administration of a study drug in controls. (22) 
Discussion
The most important result of this study is that drotrecogin alfa reduces mortality in high risk septic patients (identified in this study as those with multiple organ failure and mortality in the control group higher than 40%). While another systematic review (26) on the effects of drotrecogin alfa included randomized and non randomized studies, this meta-analysis was based solely on high quality randomized controlled trials. The preset study also confirms that drotrecogin alfa does not reduce mortality in the overall population of septic patients, as previously described. (23, 27) Moreover, in low risk patients with an APACHE II score≤25, no significantly higher risk of death was found. This finding is reassuring when confronted with the increased risk for severe complications (bleeding) described in the ADDRESS study. The Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial (23) and its following subgroup analyses (28, 29) found a consistent reduction in mortality in patients at higher risk of death, as defined by multi-organ failure or APACHE II scores higher than 25. Early enthusiasm left room for a more cautious interpretation after publication of the Administration of drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) trial, (24,30) conducted on patients with severe sepsis and low risk of death. This trial was terminated earlier for safety concerns by the monitoring committee. No difference was shown on 28 th day or in-hospital mortality between drotrecogin alfa and placebo, while an increase in serious bleeding in the drotrecogin alfa group was detected. The subsequent PROWESS-SHOCK trial was recently published by Ranieri et al. (4) This multicenter randomized controlled trial was conducted to test the hypothesis that drotrecogin alfa could reduce mortality in patients with septic shock. This population of patients was identified from the previous published trials as potentially benefitting from protein C activated. However, no significant reduction in mortality was found at 28 days (26.4% in drotreco- CI, confidence interval; RR, risk ratio. study we identified high risk patients through an ex-post analysis that identified the highest risk patient despite improved patient prognosis. A cut-off of 40% mortality was arbitrarily chosen to identify this high risk population of patients despite the secular trend of improved survival. As this population of patients was identified by an ex-post analysis, it cannot be translated as is in the clinical setting without the development of new predictive scores.
Conclusion
In high risk patients with multiple organ failure and high mortality rate in the control group, drotrecogin alfa may still have a role as a life saving treatment.
No beneficial effect in lower risk patients was found. Since no new large RCT will probably be conducted on this drug, now withdrawn from the market, an individual patient meta-analysis including all randomized controlled trials on sepsis is warranted, along with new studies on similar drugs such as protein C zymogen.
APPENDIX 1
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